In addition, to use this MRD marker in the most appropriate way, it is always necessary to perform the evaluation of WT1 expression at AML diagnosis and to use the same sample (only BM or only PB) throughout the dynamic monitoring. This evidence concerns the gene WT1 and acute myeloid leukemia.